The boundaries between ocular hypertension, primary open angle glaucoma and low tension glaucoma are indis tinct but for the purpose of this paper, established primary open angle glaucoma will be defined as the stage of the disease with identified intraocular pressure above 21 mmHg, together with characteristic forms of visual field loss significantly beyond that expected for the age of the patient. The earlier phase of the disease in which there is pressure related loss of optic nerve axons but no loss of visual field will be left in the category of ocular hyper tension but if an eye is suspected to be in this 'Quigley gap' it is usually treated as if it had primary open angle glaucoma. Evidence for this phase of the disease may be obtained from the appearance of the optic disc or analysis of the retinal nerve fibre layer, especially if sequential measurements show progressive loss. There are also sev eral innovative psychophysical and electro-physiological tests competing for the ability to predict the visual field damage but in most cases evidence is not yet secure enough to give them a reliable place in routine clinical management decisions.
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For primary open angle glaucoma with established visual field loss there is accumulating evidence from clini cal trialsl-5 on which to base choice of therapy. Informed decisions can now be made as to which of the three forms of therapy; medicines, argon laser trabeculoplasty or tra beculectomy, are appropriate to different stages of the disease depending on the level of intraocular pressure and severity of field loss. The patient's life expectancy3 and the likelihood of satisfactory compliance with treatment must also be considered. 6-8.
CHOICE OF FIRST THERAPY
The Glasgow trial of early trabeculectomy versus conven tional management of medical therapy followed by trabe culectomy for cases which were not controlled medically3,4 has provided useful information, We studied eyes with untreated intraocular pressure over 25 mmHg Eye (1992) 6,243-247 and all stages of visual field loss from mild relative scoto mas to absolute loss of field within 5° of fixation in all quadrants. Surgery has provided lower intraocular pres sure than medical therapy and the groups were equivalent for visual acuity and rate of cataract formation. In the more severely affected eyes (intraocular pressure > 30 mmHg before treatment and absolute scotomas even of small area) medical therapy failed to control approximately 70% of eyes at three years and so we now choose trabeculec tomy as the primary form of therapy for eyes with this degree of damage. Sudden loss of the last central island of visual field after operation did not occur in this trial. It has been described9 but has not been experienced by all authors 10 and others describe it as a rare event. 11 Kolkerl2 found the incidence to be similar to that occurring in medically treated cases with equivalent severity of field loss. It should therefore not be used as an excuse to avoid surgery. However, in eyes with only a small terminal island of central field, the risk of early postoperative rise in intraocular pressure should be reduced by giving carbonic anhydrase inhibitors or beta-blocker eye drops at the end of the operation.
Only about 30% of eyes with milder disease (intra ocular pressure <30 mmHg and relative scotomas) required operation at three years of follow-up3,4 and, there fore, it still seems appropriate to attempt medical control in these milder cases. This must be closely monitored as apparently satisfactory lowering of pressure by medical means does not ensure prevention of visual field deterio ration. Figure 1 shows the indications for trabeculectomy in those eyes which were not controlled medically. Eyes which were identified as having unsatisfactory reduction of pressure by medical therapy were rapidly identified and submitted to operation at a median time of four months after diagnosis. There was, as might be expected, signifi cantly greater delay before operating on those where the indication included progressive loss of field, whether or not accompanied by unsatisfactory intraocular pressure. Median time to operation was 11 months for eyes where the indication was high pressure and field loss, and 17 months for field loss with apparently normal pressure. The Mann-Whitney test indicated no significant difference in delay to operation between those where the indication was progressive field loss and high pressure compared with those with normal pressure (p = 0.35), but there was a sig nificant difference between those where the indication was high intraocular pressure alone compared with field loss at normal pressure (p = 0.01) and field loss with high pressure (p = 0.03).
The group treated by early surgery suffered less visual field loss than the one in which medical control was attempted and the difference arose entirely in the period of attempted medical control which had delayed trabeculectom y.
Visual field tests throughout the duration of the Glas gow trial were performed manually with the Tubingen Occulus perimeter and, for the sake of continuity, remained so after automated perimetry became available. Field changes were categorised in five stages: Stage 1.
Mild relative scotomas to a 1.0/lOasb target (Goldmann equivalent 1-2e) in a glaucomatous pattern. Stage 2. Abso lute scotomas, 1.0/00asb (Goldmann equivalent I-4e) in a glaucomatous pattern but greater than 10° from fixation. 
EFFECT OF DELAY BEFORE OPERATION (a) On Visual Field Loss
The detrimental effect of this delay was emphasised by the finding that those with the mildest visual field defects at diagnosis showed the most severe progressive loss and this was related to a more prolonged attempt at medical control (mean, 23 months) in these eyes compared with eyes more severely damaged at the time of diagnosis (mean, 11 months). It seemed the surgeons' perception that the eyes with less damage were at less risk of field loss led them to a more prolonged attempt at medical control, with detrimental result.
(b) On Surgical Success
Delays of this order are certainly a hazard for visual field survival but they do not seem to jeopardise the eventual success of the operation. The group mean pressure after trabeculectomy, whether as a primary procedure or for failed medical control, was identical at 15 mmHg. Fig. 2 shows in more detail the similar pattern of success of primary trabeculectomy compared with delayed trabecu lectomy. Various criteria of success are set out but more than 90% of eyes achieved worthwhile pressure reduction. Figures for success defined by various indications for sup plementary medical therapy are shown. As can be seen, medical therapy was often added when there had been sat isfactory pressure reduction after operation.
It therefore appears that two or three years of medical therapy does not make the operation less successful. More prolonged medication may, however, have a detrimental effect. In a retrospective comparison, Lavin et al. 13 found trabeculectomy less successful after a mean time of 77 months of medical therapy compared with primary trabe culectomy. Prolonged medication may carry a risk of a pemphigoid reaction in the conjunctival4 and increased amounts of inflammatory cells have been identified in con junctival biopsies after prolonged medical therapy. 15 Eyes with encapsulated filtering blebs have been reported as being more commonly associated with pro longed beta-blocker therapyl6 and a rise in pressure with topical steroids in the post-operative period was more common in eyes which had prior medical therapy than those without.17 These two causes of early postoperative pressure rise may be the same.
CHOICE OF MEDICAL THERAPY
A brief trial of closely supervised medical therapy is clearly the appropriate first line of treatment in the less severe cases. Fig. 3 shows the number of different prep-lOP unchanged by operation « 6 mm Hg reduction)
Plus, Results of delayed Trabeculectomy Fig. 2 . Success of primary trabeculectomy compared with delayed operation where the average delay while medical control was attempted was less than two years (see Fig. 1 ).
Diff erent criteria for success are given. The results are similar.
arations used in the trial of conventional management group,3 with separate data for those eventually requiring operation at a mean follow-up of 4.7 years. It can be seen that satisfactory medical control (shaded bars) was most often achieved with one or two drugs and, as might be expected, addition of further agents was less lik�ly to be useful. Fig. 4 shows the frequency of use of each main group of drugs. Pilocarpine and timolol were the most popular. The type of drug used was not related to the prob ability of successful medical control and the frequency of drug withdrawal because of side effects varied; 44% for Number of drugs attempted Fig. 3 . The number of diff erent drugs tried in the conventional management group. 3 Where there was a need to try more than one drug the probability of successful medical control diminished.
carbonic anhydrase inhibitors, 18% for adrenergic agents, 2% for timolol and 7% for pilocarpine. The low figure for timolol probably indicates that the drug was not tried in the presence of cardio-respiratory contraindications, whereas there are few contraindications for the other drugs which would prevent at least a trial of their use. Four fatal ities linked to beta-blocker eye drops were reported to the Committee of Safety of Medicines in the United Kingdom up to June 1990.18 Therefore, scrupulous care must be taken to avoid this category of drug where there is the slightest suspicion of an increased risk of bronchospasm, bradycardia or cardiac failure. Even after initial satisfac tory medical control, many eyes show gradually increas ing pressure in later years while on the same therapy. This is more likely to be caused by progression of the disease than by treatment wearing off.19
THE CHANGING ROLE OF ARGON LASER TRABECULOPLASTY
This form of treatment was introduced in 197920 and at first used in the hope of avoiding drainage surgery in eyes uncontrolled on maximum medical therapy, but it was found to delay rather than avoid surgical operation21 and is not without risk. 22 Its effectiveness depends on the experi ence and skill of the operator3 and in this it differs from trabeculectomy, the success of which does not depend on the experience of the surgeon.24,25 Argon laser trabecu loplasty is more likely to be successful in eyes with pseudoexfoliation, pigmented meshwork or lower pre treatment pressure levels, especially in patients over 60 years of age. 26 Initially successful in about 75% of cases, depending on how success is defined, it becomes gradu ally less effective with time. Between 5% and 10% of eyes escape from control each year of follow_up27-31 and the effect of treatment is less sustained in black patients. 32 Current interest in argon laser trabeculoplasty has moved from its use as a means of avoiding surgery in cases escaping from medical control, to direct comparison with medical therapy as a first line of treatment in newly diag nosed cases. If effective, it should remove the worry about compliance with medical therapy but the high rate of escape from control will require close supervision after laser treatment. Initial results for two randomised prospec tive studies comparing primary argon laser trabeculo plasty with primary medical therapy have shown either no difference in outcome or only marginal advantage for laser therapy.33,34 This is disappointing as even if the only benefit of laser therapy had been the avoidance of poor patient compliance, a greater difference might have been expected. Therefore, it seems there is little to choose between primary laser therapy and primary medical therapy.
THE RATE OF VISUAL FIELD DECAY IN PRIMARY OPEN ANGLE GLAUCOMA
The importance of achieving control in the first few months of treatment has been identified in the results of the Glasgow trial and from the rate of decay of group mean visual field in the first four years of treatment we can extrapolate to obtain slopes of visual field decay during different phases of treatment. Such extrapolation is unlikely to be an accurate description of individual cases.
There will probably be a variable rate of field loss for dif ferent individuals and even for the same individual, depending on changes in treatment and level of intraocular pressure. It will, however, serve to emphasise the hazard of unsatisfactory treatment and quantify the benefit to be gained from optimum treatment. Figure 5 shows three slopes of the derived time it might take to progress from the earliest detectable relative field defects of glaucoma to absolute loss of field within 5° of fixation, assuming that this is a linear function. Slope (a) is derived from the group mean rate of decay of visual field in the first year of conventional treatment. It includes patients later identified as uncontrolled medically and is therefore a measure of the decay which might be expected with less than perfect treatment. The disease may progress to blindness in about ten years under these conditions. Slope (b) indicates the overall decay for the first four years of conventional management, allowing inclusion of improved control achieved by surgery for those identified as being uncontrolled medically. This lengthens the pro gress of the disease to 19 years. Slope (c) takes 38 years to progress to blindness and represents stable optimum treat- ment with the unstable period of the first two years removed. It is during these two years that most operations were performed for poor medical control. This optimum slope is similar to the slope of field decay for the first four years in the group treated by trabeculectomy at diagnosis. There seems much to be gained by choosing the best treat ment. In his Lang lecture, Redmond Smith calculated that there was a field decay of about 3% per annum for treated primary open angle glaucoma.2 Again, assuming a linear decay with time, it would take about 33 years to progress to blindness, a figure almost identical with data in Fig. 5 . There were trends in his data which indicated a longer period for eyes treated by primary surgery (66 years). The most rapid projected field decay was for eyes which required operation for failed medical control (25 years).
It is known that visual fields in glaucoma patients may continue to deteriorate in some cases after apparently suc cessful lowering of intraocular pressure by trabeculec tomy.35 These eyes may have more labile intraocular pressure than those which maintain stable visual fields. 36 This explains the continued loss in average visual field performance even with optimum treatment but, as has been shown, this is a much slower loss than may occur with less satisfactory treatment.
CONCLUSION
Enough critical information is now available on the effects and side effects of the various forms of treatment that a rational choice is possible. Nihilism should be discarded. We recommend trabeculectomy soon after diagnosis with out a trial of medical therapy in eyes presenting with pres sure over 30 mmHg and with absoloute areas of field loss, even if of small area. Less advanced cases may be given a brief trial of either medical therapy or argon laser trabecu loplasty but should be offered trabeculectomy if the intra ocular pressure is not satisfactory within a few weeks. If the pressure does appear satisfactory within this period, then close monitoring of visual field should identify those who still deteriorate. Trabeculectomy is then offered with out attempting to improve medical control.
